Improved N-dimensional Data Visualization from Hyper-radial Values

Higher-dimensional data, which is becoming common in many disciplines due to big data problems, are inherently difficult to visualize in a meaningful way. While many visualization methods exist, they are often difficult to interpret, involve multiple plots and overlaid points, or require simultaneous interpretations. This research adapts and extends hyper-radial visualization, a technique used to visualize Pareto fronts in multi-objective optimizations, to become an n-dimensional visualization tool. Hyper-radial visualization is seen to offer many advantages by presenting a low-dimensionality representation of data through easily understood calculations. First, hyper-radial visualization is extended for use with general multivariate data. Second, a method is developed by which to optimally determine groupings of the data for use in hyper-radial visualization to create a meaningful visualization based on class separation and geometric properties. Finally, this optimal visualization is expanded from two to three dimensions in order to support even higher-dimensional data. The utility of this work is illustrated by examples using seven datasets of varying sizes, ranging in dimensionality from Fisher Iris with 150 observations, 4 features, and 3 classes to the Mixed National Institute of Standards and Technology data with 60,000 observations, 717 non-zero features, and 10 classes

Cyber-Physical Security with RF Fingerprint Classification through Distance Measure Extensions of Generalized Relevance Learning Vector Quantization

Radio frequency (RF) fingerprinting extracts fingerprint features from RF signals to protect against masquerade attacks by enabling reliable authentication of communication devices at the “serial number” level. Facilitating the reliable authentication of communication devices are machine learning (ML) algorithms which find meaningful statistical differences between measured data. The Generalized Relevance Learning Vector Quantization-Improved (GRLVQI) classifier is one ML algorithm which has shown efficacy for RF fingerprinting device discrimination. GRLVQI extends the Learning Vector Quantization (LVQ) family of “winner take all” classifiers that develop prototype vectors (PVs) which represent data. In LVQ algorithms, distances are computed between exemplars and PVs, and PVs are iteratively moved to accurately represent the data. GRLVQI extends LVQ with a sigmoidal cost function, relevance learning, and PV update logic improvements. However, both LVQ and GRLVQI are limited due to a reliance on squared Euclidean distance measures and a seemingly complex algorithm structure if changes are made to the underlying distance measure. Herein, the authors (1) develop GRLVQI-D (distance), an extension of GRLVQI to consider alternative distance measures and (2) present the Cosine GRLVQI classifier using this framework. To evaluate this framework, the authors consider experimentally collected Z -wave RF signals and develop RF fingerprints to identify devices. Z -wave devices are low-cost, low-power communication technologies seen increasingly in critical infrastructure. Both classification and verification, claimed identity, and performance comparisons are made with the new Cosine GRLVQI algorithm. The results show more robust performance when using the Cosine GRLVQI algorithm when compared with four algorithms in the literature. Additionally, the methodology used to create Cosine GRLVQI is generalizable to alternative measures

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

CLR457; Inhibidor Pan-PI3K; Fase ICLR457; Inhibidor Pan-PI3K; Fase ICLR457; Pan-PI3K inhibitor; Phase IBackground CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determine the maximum tolerated dose (MTD), safety, PK, and efficacy of CLR457. Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day cycle. Results CLR457 inhibited p110α, p110β, p110δ and p110γ isoforms with an IC50 of 89 ± 29 nM, 56 ± 35 nM, 39 ± 10 nM and 230 ± 31 nM, respectively. CLR457 exhibited dose-dependent antitumor activity and interfered with glucose homeostasis in PI3K-mutant tumor xenografts. 31 patients received doses ranging from 5 to 100 mg. DLTs included grade 3 hyperglycemia and rash (3). In the 100 mg cohort (n = 11), 3 (27.3%) patients had DLTs and all patients (100%) experienced ≥ grade 3 toxicity with rash (45.5%) as the most common event. The MTD was not determined. For the entire study population, stomatitis (45.2%), diarrhea (38.7%), rash (35.5%) were the most common any grade toxicities—51.6% patients experienced ≥ Grade 3 toxicity. CLR457 was rapidly absorbed with limited accumulation and linear PK. PK modeling indicated that pharmacologically active concentrations were achieved at the highest dose tested (100 mg), though no objective responses were observed. Conclusion CLR457 clinical development was terminated due to poor tolerability and limited antitumor activity. These results emphasize the difficulty of achieving a wide therapeutic index when targeting all class I PI3K-isoforms.Novartis Pharmaceuticals Corporation

Improving treatment and survival: a population‐based study of current outcomes after a hepatic resection in patients with metastatic colorectal cancer

AbstractBackgroundPopulation‐based studies historically report underutilization of a resection in patients with colorectal metastases to the liver. Recent data suggest limitations of the methods in the historical analysis. The present study examines trends in a hepatic resection and survival among Medicare recipients with hepatic metastases.MethodsMedicare recipients with incident colorectal cancer diagnosed between 1991 and 2009 were identified in the SEER(Surveillance, Epidemiology and End Results)‐Medicare dataset. Patients were stratified into historical (1991–2001) and current (2002–2009) cohorts. Analyses compared treatment, peri‐operative outcomes and survival.ResultsOf 31 574 patients with metastatic colorectal cancer to the liver, 14 859 were in the current cohort treated after 2002 and 16 715 comprised the historical control group. The overall proportion treated with a hepatic resection increased significantly during the study period (P< 0.001) with pre/post change from 6.5% pre‐2002 to 7.5% currently (P < 0.001). Over time, haemorrhagic and infectious complications declined (both P ≤ 0.047), but 30‐day mortality was similar (3.5% versus 3.9%, P = 0.660). After adjusting for predictors of survival, the use of a hepatic resection [hazard ratio (HR) = 0.40, 95% confidence interval (CI): 0.38–0.42, P < 0.001] and treatment after 2002 (HR = 0.88, 95% CI: 0.86–0.90, P < 0.001) were associated with a reduced risk of death.ConclusionsCase identification using International Classification of Diseases, 9th Revision (ICD‐9) codes is imperfect; however, comparison of trends over time suggests an improvement in multimodality therapy and survival in patients with colorectal metastases to the liver

Cool, Luminous, and Highly Variable Stars in the Magellanic Clouds from ASAS-SN: Implications for Thorne-\.Zytkow Objects and Super-Asymptotic Giant Branch Stars

Stars with unusual properties can provide a wealth of information about rare stages of stellar evolution and exotic physics. However, determining the true nature of peculiar stars is often difficult. In this work, we conduct a systematic search for cool and luminous stars in the Magellanic Clouds with extreme variability, motivated by the properties of the unusual SMC star and Thorne-\.Zytkow Object (T\.ZO) candidate HV2112. Using light curves from ASAS-SN we identify 38 stars with surface temperatures T $<$ 4800K, luminosities $\log$(L/L$_\odot$) $>$ 4.3, variability periods $>$ 400 days, and variability amplitudes $\Delta$V $>$ 2.5 mag. Eleven of these stars possess the distinctive double-peaked light curve morphology of HV2112. We use the pulsation properties and derived occurrence rates for these 12 objects to constrain their nature. From comparisons to stellar populations and models, we find that one star may be a red supergiant with large amplitude pulsations. For the other 11 stars we derive current masses of $\sim$5-10 M$_{\odot}$, below the theoretical minimum mass of $\sim$15 M$_{\odot}$ for T\.ZOs to be stable, casting doubt on this interpretation. Instead, we find that the temperatures, luminosities, mass-loss rates, and periods of these stars are consistent with predictions for super-Asymptotic Giant Branch (s-AGB) stars that have begun carbon burning but have not reached the superwind phase. We infer lifetimes in this phase of $\sim($1$-$7) $\times$ 10$^{4}$ years, also consistent with an s-AGB interpretation. If confirmed, these objects would represent the first identified population of s-AGB stars, illuminating the transition between low- and high-mass stellar evolution.Comment: 29 pages, 14 figures, 4 tables, plus Appendix. Accepted for publication in the Astrophysical Journa

546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

BackgroundTebe, a T cell receptor fused to an anti-CD3 effector, can redirect T cells to target gp100+ cells and in Ph3, demonstrated overall survival (OS) benefit as monotherapy in metastatic uveal melanoma. In Ph2, any tumor shrinkage (44% of patients) was a better predictor of OS than response rate. In Ph1, Tebe had monotherapy activity in mCM, also a gp100+ tumor, with 1-year OS ~74% in PD-1 naïve mCM. A Ph1 dose escalation of tebe with durva (anti-PD-L1) and/or treme (anti-CTLA4) was conducted in pre-treated mCM [NCT02535078], with nearly all patients having prior PD1-treatment, and where recently reported therapies have 1-yr OS of ~55%.MethodsHeavily pre-treated HLA-A2+ mCM patients received weekly IV tebe alone (Arm 4) or with increasing doses of durva and/or treme (Arm 1–3) administered IV monthly starting day 15 of each cycle. Primary objective was to identify RP2D of combination therapy. Secondary objectives included adverse events (AE) and efficacy.Results112 pts received ≥1 tebe dose. Median age was 59, 77% were ECOG 0, and 37% were BRAFm (of which 71% received prior BRAFi/MEKi). 91% of pts were 2L+, while 74% were 3L+. 103 (92%) received prior PD-1 inhibitor, of which 87% also received prior ipilimumab. 43 pts received tebe + durva (Arm 1), 13 received tebe + treme (Arm 2), 29 received triplet therapy (Arm 3), and 27 received tebe alone (Arm 4). Maximum target doses of tebe (68 mcg) + durva (20 mg/kg) and treme (1 mg/kg) were tolerated. MTD was not formally identified for any arm. Two DLTs occurred: prolonged grade 3 rash (Arm 1) and grade 2 diarrhea leading to treatment delay (Arm 2). Related AEs that were Grade ≥3 or led to discontinuations were: 44%/0% (Arm 1), 23%/0% (Arm2), 38%/7% (Arm3), 26%/4% (Arm 4). There were no treatment-related deaths.In prior PD-1 pts, tumor shrinkage occurred in 36% and 1-yr OS was 68%. Of 51 evaluable PD-1 resistant pts (best response CR/PR/SD to prior PD1), tumor shrinkage occurred in 28% and 1-yr OS was 73% (figure 1). In 35 evaluable PD-1 refractory pts (prior best response PD), tumor shrinkage occurred in 49% and 1-yr OS was 61%. For 38 prior PD-1 pts who received ≥10mg/kg durva, 1-yr OS was 81%.Abstract 546 Figure 1% tumor change from baseline in evaluable patients with known response to prior PD1 exposureConclusionsTebe with anti-PD-L1 and/or anti-CTLA4 had an acceptable safety profile. Tebe + durva demonstrated durable tumor shrinkage and promising 1-yr OS rates in prior-PD1 treated mCM relative to recent reports.Trial RegistrationNCT02535078Ethics ApprovalThe institutional review board or independent ethics committee at each center approved the trial. The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines

Understanding amine catalyzed silica polymerization : diatoms as bioarchitects.

Current state-of-the-art biomimetic methodologies employed worldwide for the realization of self-assembled nanomaterials are adequate for certain unique applications, but a major breakthrough is needed if these nanomaterials are to obtain their true promise and potential. These routes typically utilize a 'top-down' approach in terms of controlling the nucleation, growth, and deposition of structured nanomaterials. Most of these techniques are inherently limited to primarily 2D and simple 3D structures, and are therefore limited in their ultimate functionality and field of use. Zeolites, one of the best-known and understood synthetic silica structures, typically possess highly ordered silica domains over very small length scales. The development of truly organized and hierarchical zeolites over several length scales remains an intense area of research world wide. Zeolites typically require high-temperature and complex synthesis routes that negatively impact certain economic parameters and, therefore, the ultimate utility of these materials. Nonetheless, zeolite usage is in the tons per year worldwide and is quickly becoming ubiquitous in its applications. In addition to these more mature aspects of current practices in materials science, one of the most promising fields of nanotechnology lies in the advent and control of biologically self-assembled materials, especially those involved with silica and other ceramics such as hydroxyapatite. Nature has derived, through billions of years of evolutionary steps, numerous methods by which fault-tolerant and mechanically robust structures can be created with exquisite control and precision at relatively low temperature ranges and pressures. Diatoms are one of the best known examples that exhibit this degree of structure and control known that is involved with the biomineralization of silica. Diatoms are eukaryotic algae that are ubiquitous in marine and freshwater environments. They are a dominant form of phytoplankton critical to global carbon fixation. The silicified cell wall of the diatom is called the frustule, and the intricate silica structure characteristic of a given species is known as the valve. There are two general classes of diatoms, based on their overall morphologies, the pennate and centric. Diatoms achieve their silicified structures in exact fashion through genetically inspired design rules coupled with precisely directed biochemistry occurring at temperatures ranging from a few degrees Celsius (polar species) to temperatures just over room temperature (tropical species). Different species of diatoms produce markedly different structures. To start with, there are two basic types of frustule macromorphologies: pennate diatoms display bilateral symmetry and centric diatoms show radial symmetry. There are thousands of permutations of these two basic forms and the micromorphology of the valve can be quite complex with all types of pore arrangements and morphologies (Figure 1.1). The detailed morphology of the cell wall of a given diatom species is reproduced with exactness, because the process is genetically encoded. Three types of cell wall proteins have been identified in diatoms; the frustulins, pleuralins, and silaffins. Frustulins are cell wall proteins that form an organic coat to protect the silica structures from dissolution into the aqueous environment. Pleuralins are associated with a specific subcomponent of the frustule during cell division, and play a role in hypotheca-epitheca development. Silaffins from Cylindrotheca fusiformis are short chain-length peptides that play a direct role in the silica polymerization process, and possess unique biochemical post-translation functionalization. Larger proteins with silaffin activity have recently been described in Thalassiosira pseudonana. Frustulins and pleuralins play no role in silica polymerization or structure formation in diatoms, whereas the silaffins are one of the primary polymerization determinants. In addition to the silaffins, a class of long-chain polyamines associated with diatom silica has been identified, and shown to also be involved in the silica polymerization process. The silaffins and polyamines are likely to be the two major determinants of silica polymerization in diatoms. Their involvement in the formation of higher order structure is unclear; there have been suggestions that they self-assemble in various combinations to form the final frustule structure but these are highly speculative as there is no substantial data to support this. It is clear from a long history of electron microscopic observations that a major determinant of silica structure in diatoms is generated by growth and molding of the silica deposition vesicle (SDV), the specialized intracellular compartment were the frustule is made. Diatoms are the focus of research activity on several fronts, including the processes by which their distinct silica frustules are formed

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

Introduction: Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated. Methods: In a phase 1b study (NCT02099058), adult patients (≥18 y) with advanced NSCLC received combination therapy with Teliso-V (1.6, 1.9, or 2.2 mg/kg, every 2 wk) plus nivolumab (3 mg/kg, 240 mg, or per locally approved label). The primary objective was to assess safety and tolerability; secondary objectives included the evaluation of antitumor activity. Results: As of January 2020, a total of 37 patients received treatment with Teliso-V (safety population) in combination with nivolumab; 27 patients (efficacy population) were c-Met immunohistochemistry-positive. Programmed death-ligand 1 (PD-L1) status was evaluated in the efficacy population (PD-L1-positive [PD-L1+]: n = 15; PD-L1-negative [PD-L1-]: n = 9; PD-L1-unknown: n = 3). The median age was 67 years and 74% (20 of 27) of patients were naive to immune checkpoint inhibitors. The most common any-grade treatment-related adverse events were fatigue (27%) and peripheral sensory neuropathy (19%). The pharmacokinetic profile of Teliso-V plus nivolumab was similar to Teliso-V monotherapy. The objective response rate was 7.4%, with two patients (PD-L1+, c-Met immunohistochemistry H-score 190, n = 1; PD-L1-, c-Met H-score 290, n = 1) having a confirmed partial response. Overall median progression-free survival was 7.2 months (PD-L1+: 7.2 mo; PD-L1-: 4.5 mo; PD-L1-unknown: not reached). Conclusions: Combination therapy with Teliso-V plus nivolumab was well tolerated in patients with c-Met+ NSCLC with limited antitumor activity

Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma

Introduction: Benchmarking in surgery has been proposed as a means to compare results across institutions to establish best practices. We sought to define benchmark values for hepatectomy for intrahepatic cholangiocarcinoma (ICC) across an international population. Methods: Patients who underwent liver resection for ICC between 1990 and 2020 were identified from an international database, including 14 Eastern and Western institutions. Patients operated on at high-volume centers who had no preoperative jaundice, ASA class &lt;3, body mass index &lt;35 km/m2, without need for bile duct or vascular resection were chosen as the benchmark group. Results: Among 1193 patients who underwent curative-intent hepatectomy for ICC, 600 (50.3%) were included in the benchmark group. Among benchmark patients, median age was 58.0 years (interquartile range [IQR] 49.0–67.0), only 28 (4.7%) patients received neoadjuvant therapy, and most patients had a minor resection (n = 499, 83.2%). Benchmark values included ≥3 lymph nodes retrieved when lymphadenectomy was performed, blood loss ≤600 mL, perioperative blood transfusion rate ≤42.9%, and operative time ≤339 min. The postoperative benchmark values included TOO achievement ≥59.3%, positive resection margin ≤27.5%, 30-day readmission ≤3.6%, Clavien-Dindo III or more complications ≤14.3%, and 90-day mortality ≤4.8%, as well as hospital stay ≤14 days. Conclusions: Benchmark cutoffs targeting short-term perioperative outcomes can help to facilitate comparisons across hospitals performing liver resection for ICC, assess inter-institutional variation, and identify the highest-performing centers to improve surgical and oncologic outcomes.</p